Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Overview of attention for article published in Drug Design, Development and Therapy, July 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 120 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 16 publications that cite this research output.

16

The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.

Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations

Article in Genes (December 2023)

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation

Article in Open Heart (March 2023)

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process

Article in Drugs in R&D (September 2021)